Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Obbink K"'
Autor:
BUSS, B. F., JOSHI, M. V., O'KEEFE, A. L., ALLENSWORTH, C. D., GARVEY, A., OBBINK, K., MANDERNACH, S., SAFRANEK, T. J.
Publikováno v:
Epidemiology and Infection, 2016 Jul 01. 144(9), 1807-1817.
Externí odkaz:
https://www.jstor.org/stable/26515680
Autor:
Wang J, Hughes TP, Kok CH, Saunders VA, Frede A, Groot-Obbink K, Osborn M, Somogyi AA, D'Andrea RJ, White DL, Wang, J, Hughes, T P, Kok, C H, Saunders, V A, Frede, A, Groot-Obbink, K, Osborn, M, Somogyi, A A, D'Andrea, R J, White, D L
Publikováno v:
British Journal of Cancer; 5/22/2012, Vol. 106 Issue 11, p1772-1778, 7p
Publikováno v:
Prehospital Emergency Care; 1999, Vol. 3 Issue 3, p231-238, 8p
Publikováno v:
In Journal of Lipid Research August 1997 38(8):1562-1570
Autor:
Andrew A. Somogyi, Deborah L. White, Amity Frede, Michael Osborn, Richard J D'Andrea, Verity A Saunders, Chung H. Kok, J Wang, Timothy P. Hughes, Kelvin GrootObbink
Publikováno v:
British Journal of Cancer
Background: The human organic cation transporter-1 (OCT-1) is the primary active protein for imatinib uptake into target BCR-ABL-positive cells. Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used by chronic myeloid leukaemia (CML) pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aa292b015cf9e23b8b93da8e4b7f265
https://doi.org/10.1038/bjc.2012.173
https://doi.org/10.1038/bjc.2012.173
Autor:
Wright LC; Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, NSW, Australia. lesleyw@icpmr.wsahs.nsw.gov.au, Obbink KL, Delikatny EJ, Santangelo RT, Sorrell TC
Publikováno v:
European journal of biochemistry [Eur J Biochem] 2000 Jan; Vol. 267 (1), pp. 68-78.